Method and System for Treating Non-Alcoholic Fatty Liver Disease

• US 20170106026A1
• Filed: 12/28/2016
• Published: 04/20/2017
• Est. Priority Date: 02/04/2011
• Status: Active Grant

• Current Assignee: Seed Health, Inc.
• Original Assignee: Joseph E. Kovarik
• Inventors: Kovarik, Joseph E.
• Granted Patent: US 10,245,288 B2
• Time in Patent Office: Days
• CPC Class Codes: A61F 5/0003 Apparatus for the treatment of obesity; Anti-eating devices surgical instruments or methods for treatment of obesity, devices specially adapted therefor A61B17/00; hollow or tubular parts of organs A61F2/04
• CPC Class Codes: A61K 35/741 Probiotics probiotic yeast, e.g. saccharomyces A61K36/06
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis

Abstract

A method and system for treating non-alcoholic fatty liver disease (NAFLD) involves the modulation of the gut microbial of a person suffering from NAFLD, and in particular the provision of a probiotic therapy configured to reduce liver aminotransferases, total-cholesterol, TNF-α and to improve insulin resistance in NAFLD patients.

Claims

1. A method for treating non-alcoholic fatty liver disease, comprising:

providing to an individual in need thereof an effective amount of a composition comprising bacteria modified using a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system so that the bacteria is able to produce desired levels of anti-bodies to oxidized low density lipoprotein (oxLDL).

2. The method as set forth in claim 1, further comprising administering at least 6 grams per day of fiber to the individual.

3. A method for treating non-alcoholic fatty liver disease, comprising:

establishing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus, Bifidobacterium, and Streptococcus species; and

administering at least 6 grams per day of fiber to the individual to maintain the beneficial bacteria in the gut of the individual.

4. The method as set forth in claim 3, further comprising:

comprising providing to the individual'"'"'s gut microbiome bacteria that have been treated with a CRISPR-Cas or CRISPR-Cpf1 system to one of;

reverse antibiotic resistance; and

render ineffective a virulence factor of said population of beneficial bacteria.

5. The method as set forth in claim 3, further comprising:

administering a composition including a therapeutically effective amount of Prevotella bacteria that has been modified in a manner that reduces the effect of at least one of the virulence factors of Prevotella bacteria.

6. The method as set forth in claim 3, further comprising:

a

administering to an individual an effective amount of a bacteriaof the Bacteroides family that has been modified to reduce the amount of a ligand-activated transcription factor.

8. The method as set forth in claim 3, further comprising:

administering bifidobacteria that has been modified using a CRISPR-Cas system to increase the level of butyrate by said bifidobacteria.

9. The method as set forth in claim 3, wherein the individual is further administered an amount of H. pylori bacteria that has been modified using CRISPR-Cas to render said H. pylori more susceptible to particular antibiotics.

10. The method as set forth in claim 3, further comprising administering at least 6 grams per day of fiber to the individual.

7. A method for treating non-alcoholic fatty liver disease, comprising:

providing to an individual in need thereof an effective amount of a composition comprising modified L. reuteri bacteria, said L. reuteri bacteria modified using CRISPR-Cas and/or Cpf1 systems in a manner such that said bacteria are able to survive the conditions in the duodenum and jejunum of the small intestine of a human.